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To raise monoclonal antibodies recognizing cancer-associated alterations of the carbohydrate structure of 
glycoproteins, Balb/c mice were immunized with human colonic cancer cells (LS 180 from ATCC). One 
of the generated hybridomas produced a monoclonal antibody that bound to the carbohydrate moiety of 
mucin-type glycoproteins from LS 180. The antibody did not bind to glycoproteins from another colonic 
cancer cell line, SW 1116, or to glycolipids from any of the colonic cancer cell lines. The antibody bound 
to ovine and bovine submaxillary mucins (OSM and BSM). NeuAcct2~6GalNAc seemed to be involved 
in the epitope. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Alterations of carbohydrate chains of glycocon- 
jugates are often associated with malignant 
transformation of cells. A number of cancer- 
associated carbohydrate antigens have been iden- 
tified by the use of monoclonal antibodies [1]. 
Most of the antigens recognized are glycolipids and 
are often related to blood group antigens. Struc- 
tural studies of the epitopes have also been per- 
formed using glycolipids, but the alterations 
specifically expressed on sugar chains of glycopro- 
teins have not been studied extensively. 
By injecting human cancer cells (LS 180 cells) in- 
to mice and selecting hybridomas which secrete an- 
tibodies reacting with glycopeptides from the 
cancer cells, we have obtained five monoclonal an- 
tibodies recognizing carbohydrate moiety of 
glycoproteins (Fukui, S. et al., to be published 
elsewhere). Here, we describe the properties of one 
such monoclonal antibody, designated MLS 102. 
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2.1. Materials 
Human colonic cancer cells, LS 180 and 
SW 1116, were obtained from ATCC, Rockville. 
NeuAca2-~31actose, NeuAca2~ 6lactose and 
NeuAc~2 ~ 3Gal~l ~ 3(NeuAc~2 ~ 6)GalNAc~I 
4Gal/Yl~4Glc from bovine colostrum were gifts 
from Dr Y. Uchida (Marukin Shoyu Co.). N- 
Acetylneuraminic acid was from Nakarai (Kyoto) 
and N-glycolylneuraminic acid from Sigma (St. 
Louis, MO). 
2.2. Methods 
Ovine and bovine submaxillary mucins were 
prepared according to Tettamanti and Pigman [2], 
and porcine submaxillary mucin as described by 
De Salegui and Plonska [3]. 
The cell membrane glycoproteins were isolated 
from LS 180 cells according to Funakoshi and 
Yamashina [4] and extensively digested with pro- 
nase. The digest was fractionated by gel filtration 
on Sephadex G-50 to obtain mucin-type glycopep- 
tides (G-50I) and serum-type glycopeptides 
(G-50II) [5]. The glycolipid fraction was separately 
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Fig. 1. Activities of glycoproteins inhibiting the binding 
of MLS 102 to G-50I. (Abscissa) Glycoprotein 
concentrations expressed as ialic acid; (ordinate) 
amounts of MLS 102 bound to the wells expressed as 
bound protein A. (.) OSM, (©) G-50I, (a) BSM, (zx) 
PSM. 
prepared by extracting the packed cells with 
chloroform/methanol.  
Reactivities of mucin-type glycoproteins and 
several sugars with MLS 102 were determined by 
measuring their ability to inhibit the binding of 
MLS 102 to G-50I. Wells of a polyvinyl chloride 
plate (96 wells, Corster) were coated with G-50I 
(about 500 ng in each well), then the uncoated area 
of the wells was covered by 1% bovine serum 
albumin (BSA) in 20 mM phosphate-buffered 
saline (PBS), pH 7.2. An appropriate amount of 
MLS 102 in PBS containing 0.1% BSA (10#1) and 
aqueous olution of glycoproteins or sugars (10 #1) 
were added successively. The plate was left 
standing overnight at 4°C. The wells were washed 
with PBS containing 1% BSA, then 125I-labelled 
protein A (12.5 ng with about 100000 cpm in 50 #1 
PBS containing 0.1% BSA) was added and in- 
cubated at room temperature for 2 h. The wells 
were washed with PBS (150#1) three times, then 
each well was cut out from the plate, and radio- 
activities were counted in a gamma spectrophoto- 
meter (Gamma-5500, Beckman). 
3. RESULTS AND DISCUSSION 
One of the monoclonal antibodies raised against 
LS 180 cells, designated MLS 102, appeared to 
recognize cancer-associated antigens in cancers of 
intestine, esophagus and ovary as assessed from 
histological studies using fluorescein-labelled anti- 
mouse IgG rabbit IgG. The antibody bound to 
both the cells and their secretions. MLS 102 
reacted with G-50I, but not with G-50II. Sialidase 
treatment of G-50I abolished the reactivity. 
No reaction was observed with glycolipids from 
LS 180 or another colonic cancer cell line, 
SW 1116, or with glycolipids from various sources 
such as bovine brain and human meconium. Thus, 
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Fig.2. Reactivities of sialic acids and sialyl oligosaccharides with MLS 102 determined by inhibition of binding of 
MLS 102 to G-50I. (©) NeuAca,2~6GalNAc, (a) NeuAcol2~61actose, ( i )  N-acetylneuraminic acid, (4) 
NeuAcol2~31actose, (n) N-glycolylneuraminic a id, (o) OSM as a reference. 
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MLS 102 appeared to differ from the antibodies 
recognizing sialylated terminal structures of 
gangliosides as exemplified by the sialyl Le a struc- 
ture [6]. Glycopeptides, both mucin and serum 
types, prepared from SW 1116 did not react with 
MLS 102. The antibody did not react with seminal 
fluid, amniotic fluid, cord serum, colostrum, 
maternal serum and saliva from human sources. 
The only immunoreactive glycopeptides or 
glycoproteins of human origin other than G-50I so 
far tested were a mucin from meconium and a rec- 
tal adenocarcinoma glycoprotein [7] (not shown). 
Only about 10%0 of G-50I was reactive with 
MLS 102, as determined by immunoaffinity 
chromatography using a column constructed by 
coupling MLS 102 to Sepharose 4B. 
Interestingly, MLS 102 reacted with OSM and 
BSM with less activity towards porcine submax- 
illary mucin (fig. 1). On fractionation using the im- 
munoaffinity column, about 90% of OSM, based 
on sialic acid content, was retained and eluted, 
whereas about 40% of BSM was retained. 
Most of the carbohydrate moiety of OSM is 
known to be NeuAca2~6GalNAcad--* [8]. The 
disaccharide could be released from OSM by 
alkaline-borohydride treatment as a sugar alcohol 
or by hydrazine treatment followed by re-N- 
acetylation as a reducing sugar (unpublished). The 
disaccharide-alcohol had no inhibitory activity 
towards the reaction between MLS 102 and G-50I, 
but the reducing disaccharide had significant ac- 
tivity, as shown in fig.2. Unlike Hanganutziu- 
Deicher antigen [9], N-glycolylneuraminic a id did 
not react with MLS 102. The inhibitory activity 
seemed to be confined to NeuAca2~6GalNAc (or 
NeuAc~2~6Gal  to some extent), and practically 
no activity was found for 2--,3-1inked sialic acid 
residue. However, when the N-acetylgalactos- 
amine to which N-acetylneuraminic a id is linked 
at C-6 is substituted at C-3, the reactivity seems 
to be lost since the following oligosaccharide had 
no activity: NeuAca2~ 3Ga16'l ~ 3(NeuAccr2~ 6)- 
GalNAcfl l-- .4Gal~l ~4Glc  isolated from bovine 
colostrum. This may be applied to glycolipids as 
well. Disialoganglioside having the colostrum 
oligosaccharide structure, described above, as the 
carbohydrate moiety was not reactive with 
MLS 102. Glycolipids with the terminal 
NeuAccr2~6GalNAc structure would be reactive, 
but the occurrence of such glycolipid has so far not 
been reported. 
The reactivity of OSM was, however, much 
higher compared to that of NeuAca2--.6GalNAc 
(fig.2). This would probably be due to the occur- 
rence of a cluster of the disaccharide on the 
polypeptide as was found for the Ca antigen [10]. 
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